New insights into the mechanisms of venous thrombosis.
暂无分享,去创建一个
[1] D. Lombardo,et al. Cancer cell–derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo , 2009, The Journal of experimental medicine.
[2] T. Wakefield,et al. Critical review of mouse models of venous thrombosis. , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[3] Gary H Lyman,et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.
[4] G. Lip,et al. Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation , 2009 .
[5] A. Iorio,et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.
[6] P. Romundstad,et al. Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.
[7] A. Wolberg,et al. Plasma and cellular contributions to fibrin network formation, structure and stability , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] Vandenbroucke. UvA-DARE ( Digital Academic Repository ) Oral contraceptives and the risk of venous thrombosis , 2001 .
[9] R. Cummings,et al. Role of PSGL-1 binding to selectins in leukocyte recruitment. , 1997, The Journal of clinical investigation.
[10] S. Basili,et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. , 2000, Atherosclerosis.
[11] D. Johns,et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. , 2012, The Journal of clinical investigation.
[12] E. Oger,et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study , 2004, Fundamental & clinical pharmacology.
[13] N. Mackman,et al. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[14] C. Gonsalves,et al. May-Thurner Syndrome: Case Report and Review of the Literature Involving Modern Endovascular Therapy , 2009, Vascular.
[15] T. Mayadas,et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. , 1996, The Journal of clinical investigation.
[16] E. Tremoli,et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. , 2007, Pharmacological research.
[17] R. Hubbard,et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting , 2006, The Lancet.
[18] Jean-MarieFreyssinet,et al. Cellular Mechanisms Underlying the Formation of Circulating Microparticles , 2011 .
[19] W M O'Fallon,et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.
[20] C. Benjamin,et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets , 1992, Nature.
[21] W. Aird,et al. Vascular-bed--specific hemostasis and hypercoagulable states. , 1999, The New England journal of medicine.
[22] T. Wakefield,et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation , 2008, Thrombosis and Haemostasis.
[23] D. Neuberg,et al. Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy , 2009, Clinical Cancer Research.
[24] T. Renné,et al. Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo , 2009, Cell.
[25] S. Jackson. Arterial thrombosis—insidious, unpredictable and deadly , 2011, Nature Medicine.
[26] A. Clemens,et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[27] K. Steinbeck,et al. Increased tissue factor activity in monocytes from obese young adults , 2010, Clinical and experimental pharmacology & physiology.
[28] C. Esmon. The protein C pathway. , 2003, Critical care medicine.
[29] G. Broze,et al. Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.
[30] E. Horváth-Puhó,et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study , 2009, Journal of thrombosis and haemostasis : JTH.
[31] D. Wagner,et al. Neutrophil extracellular traps promote deep vein thrombosis in mice , 2012, Journal of thrombosis and haemostasis : JTH.
[32] P. Libby,et al. An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.
[33] K. Mann,et al. The dynamics of thrombin formation. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[34] M. Baker,et al. Effect of anatomic variations on deep venous thrombosis of the lower extremity. , 1986, AJR. American journal of roentgenology.
[35] W. Bargar,et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. , 1998, Archives of internal medicine.
[36] F. Rosendaal,et al. HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[37] S. Watson. Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. , 2009, Current pharmaceutical design.
[38] G. Raskob,et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[39] A. Bloom. Haemostasis and thrombosis , 1981 .
[40] M. Prins,et al. Increased Fibrinolytic Activity during Use of Oral Contraceptives Is Counteracted by an Enhanced Factor XI-independent down Regulation of Fibrinolysis , 2000, Thrombosis and Haemostasis.
[41] E. Myers,et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. , 2006, American journal of obstetrics and gynecology.
[42] Alberto Smith,et al. Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions. , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[43] N. Mackman,et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. , 2010, Thrombosis research.
[44] A. Khorana. Venous thromboembolism and prognosis in cancer. , 2010, Thrombosis research.
[45] F. Rosendaal,et al. Venous thrombosis in the elderly , 2007, Journal of thrombosis and haemostasis : JTH.
[46] B. Osterud,et al. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. , 2009, Scandinavian journal of haematology.
[47] S. Shirasawa,et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. , 2005, Blood.
[48] Sanjiv J. Shah,et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. , 2011, Thrombosis research.
[49] N. Key,et al. Current treatment of venous thromboembolism. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[50] R. Cummings,et al. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. , 1997, The Journal of clinical investigation.
[51] B. Furie,et al. Mechanisms of thrombus formation. , 2008, The New England journal of medicine.
[52] C. Esmon,et al. Valves of the deep venous system: an overlooked risk factor. , 2007, Blood.
[53] S. Goldhaber. Epidemiology of pulmonary embolism. , 2001, Seminars in vascular medicine.
[54] M. Woodward,et al. EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY I. ILLUSTRATIVE REFERENCE RANGES BY AGE, SEX AND HORMONE USE , 1997, British journal of haematology.
[55] S. Eichinger,et al. Deep vein thrombosis , 2005, The Lancet.
[56] C HISCOCK,et al. EPIDEMICS OF TYPHOID FEVER. , 1964, Lancet.
[57] C. Esmon. The regulation of natural anticoagulant pathways , 1987, Science.
[58] T. Renné,et al. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? , 2007, Journal of thrombosis and haemostasis : JTH.
[59] S. Robson,et al. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. , 2006, Blood cells, molecules & diseases.
[60] A. James. Venous thromboembolism in pregnancy. , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[61] James H Morrissey,et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. , 2010, Blood.
[62] M. Thomas,et al. The iliac compression syndrome , 1965, The British journal of surgery.
[63] T. Lau,et al. Venous Thromboembolism in Pregnant Chinese Women , 2001, Obstetrics and gynecology.
[64] N. Mackman. Triggers, targets and treatments for thrombosis , 2008, Nature.
[65] N. Mackman,et al. Microparticles in Hemostasis and Thrombosis , 2011, Circulation research.
[66] S. Noble,et al. Epidemiology and pathophysiology of cancer-associated thrombosis , 2010, British Journal of Cancer.
[67] Nigel Mackman,et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.
[68] Paul Enright,et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. , 2004, The American journal of medicine.
[69] J. Hoover-Plow,et al. The functions of plasminogen in cardiovascular disease. , 2004, Trends in cardiovascular medicine.
[70] K. Bauer,et al. Role of antithrombin III as a regulator of in vivo coagulation. , 1991, Seminars in hematology.
[71] K. Bremme. Haemostatic changes in pregnancy. , 2003, Best practice & research. Clinical haematology.
[72] Anetta Undas,et al. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[73] S. Basili,et al. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.
[74] L. Melton,et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.
[75] A. D’Angelo,et al. The protein C pathway and sepsis. , 2012, Thrombosis research.
[76] G. Broze. Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.
[77] M. Prins,et al. Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study , 2000, Thrombosis and Haemostasis.
[78] P. Reitsma,et al. Genetics of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[79] James H Morrissey,et al. Polyphosphate modulates blood coagulation and fibrinolysis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[80] K. Preissner,et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation , 2007, Proceedings of the National Academy of Sciences.
[81] A. Khorana,et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.
[82] J. Emmerich,et al. Venous Thromboembolism: Risk Factors for Recurrence , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[83] G. Johnson,et al. Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty , 2009, Thrombosis and Haemostasis.
[84] B. Lämmle,et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. , 2011, Blood.
[85] D. W. Barritt,et al. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. , 1960, Lancet.
[86] WolfgangMueck,et al. Rivaroxaban: A New Oral Factor Xa Inhibitor , 2010 .
[87] A. van der Vliet,et al. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? , 2011, Annual review of physiology.
[88] J. Eikelboom,et al. Update on Antithrombotic Therapy: New Anticoagulants , 2010, Circulation.
[89] N. Mackman. Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[90] P. Libby,et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.
[91] P. Reitsma,et al. Mechanistic View of Risk Factors for Venous Thromboembolism , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[92] Z. Ruggeri,et al. The role of von Willebrand factor in thrombus formation. , 2007, Thrombosis research.
[93] A. Marcus,et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. , 1997, The Journal of clinical investigation.
[94] M. Cybulsky,et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.
[95] K. Preissner,et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases , 2010, Nature Medicine.
[96] M. Dávila,et al. Tissue Factor-Bearing Microparticles Derived from Tumor Cells: Impact on Coagulation Activation. , 2006 .
[97] A. Walch,et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo , 2012, The Journal of experimental medicine.
[98] P. Fontana,et al. Cell-derived microparticles in haemostasis and vascular medicine , 2009, Thrombosis and Haemostasis.
[99] J. Hartwig,et al. Extracellular DNA traps promote thrombosis , 2010, Proceedings of the National Academy of Sciences.
[100] C. Esmon,et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. , 1987, The Journal of clinical investigation.
[101] E. Oger. Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.
[102] Chaoyang Li,et al. Increasing Trends in Waist Circumference and Abdominal Obesity among U.S. Adults , 2007, Obesity.
[103] K Konstantopoulos,et al. Perspectives Series: Cell Adhesion in Vascular Biology Effects of Fluid Dynamic Forces on Vascular Cell Adhesion , 1996 .
[104] G. Soff. A New Generation of Oral Direct Anticoagulants , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[105] C. Marosi,et al. Prediction of venous thromboembolism in cancer patients. , 2010, Blood.
[106] H. Meiselman,et al. A local increase in red blood cell aggregation can trigger deep vein thrombosis: evidence based on quantitative cellular ultrasound imaging , 2011, Journal of thrombosis and haemostasis : JTH.
[107] N. Mackman. Tissue-Specific Hemostasis in Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[108] M. Gent,et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty , 2010, Thrombosis and Haemostasis.
[109] M. Allman-Farinelli. Obesity and venous thrombosis: a review. , 2011, Seminars in thrombosis and hemostasis.
[110] C. Esmon,et al. The link between vascular features and thrombosis. , 2011, Annual review of physiology.
[111] C. O. Kennedy. A controlled trial , 1971, British Homeopathic Journal.
[112] F. Rosendaal,et al. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use , 2003, Thrombosis and Haemostasis.
[113] I. Silver,et al. The PO2 in venous valve pockets: Its possible bearing on thrombogenesis , 1981, The British journal of surgery.
[114] G. Lip,et al. The hypercoagulable state of malignancy: pathogenesis and current debate. , 2002, Neoplasia.
[115] T. Wakefield,et al. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. , 2009, Thrombosis research.
[116] J. Chou,et al. Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-Selectin , 2003, The Journal of experimental medicine.
[117] R. Bertina,et al. Microparticle‐associated tissue factor activity in cancer patients with and without thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[118] G. Newton,et al. Emerging mechanisms of neutrophil recruitment across endothelium. , 2011, Trends in immunology.
[119] R. Virchow,et al. Gesammelte Abhandlungen zur wissenschaftlichen Medicin , 1856 .
[120] W. Fay. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. , 2004, Trends in cardiovascular medicine.
[121] E. Tremoli,et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[122] G. Lippi,et al. Arterial thrombus formation in cardiovascular disease , 2011, Nature Reviews Cardiology.
[123] T. Wakefield,et al. Mechanisms of venous thrombosis and resolution. , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[124] R. Bertina,et al. Microparticle-Associated Tissue Factor Activity: A Link between Cancer and Thrombosis?. , 2005 .